€0.27
-0.02 (-5.86%)
EUR · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CYAD.BR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal CancerNCT04991948The Occurrence of Dose Limiting Toxicities (DLT) during the 'DLT reporting period'Open-label · Treatment | Phase 1 | Recruiting | Drug: CYAD-101, FOLFOX, Pembrolizumab | Unresectable Metastatic Colorectal Cancer | 34 | 2023-08-21 | 2022-03-09 |
| Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple MyelomaNCT04613557Occurrence of Dose Limiting ToxicitiesOpen-label · Treatment | Phase 1 | Active, not recruiting | Biological: CYAD-211 · Drug: Endoxan, Fludara | Relapse/Refractory Multiple Myeloma | 18 | 2022-12-21actual | 2023-08-31 |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02NCT04167696Occurrence of Dose Limiting Toxicities as defined per protocol in order to define the final recommended dose.Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: CYAD-02 · Drug: ENDOXAN, Fludara | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 27 | Dec 2021 | 2020-06-09 |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cellsNCT03692429Occurence of Dose Limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CYAD-101, FOLFOX, FOLFIRI | Unresectable Metastatic Colorectal Cancer | 49 | 2021-11-28 | 2020-11-20 |
| A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer IndicationsNCT03018405Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of NKR-2 infusionNon-randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Biological: NKR-2 cells | Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM) | 146 | May 2021 | 2019-09-19 |
| Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver MetastasesNCT03310008The occurrence of Dose Limiting Toxicities (DLT) in all patients during the study treatment until 14 days after the first NKR-2 study treatment administrationNon-randomized · Open-label · Treatment | Phase 1 | Unknown status | Biological: NKR-2 cells | Colon Cancer Liver Metastasis | 36 | May 2021 | 2020-06-16 |
| DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2NCT03466320The occurrence of Dose-limiting toxicities (DLT) during the study treatment until 3 weeks after first NKR-2 study treatment administration.Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: NKR-2 | AML, MDS | 21 | 2021-02-01actual | 2021-05-04 |
| Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIALNCT02317458Efficacy of C3BS-CQR-1 injection based on a hierarchical composite scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Unknown status | Biological: Experimental, Sham comparator | Heart Failure | 400 | Mar 2020 | 2016-07-11 |
| EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2NCT03612739The occurrence of Dose Limiting toxicities (DLT) during the study treatment until 6 months after initial treatment.Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Sponsor decision | Biological: NKR-2 CAR-T Cells | AML, Adult, Myelodysplastic Syndromes | 0 | May 2019 | 2019-10-29 |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-LigandsNCT02203825Safety and feasibility of intravenous administration of CM-CS1 T-cells.Open-label · Treatment | Phase 1 | Completed | Biological: CM-CS1 T-cell infusion | Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma | 12 | Mar 2018actual | 2018-06-01 |
| Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal CancerNCT03370198The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Difficulties in patient recruitment and clinical strategy modification based on new clinical data generated in the NKR-2 early development. | Biological: NKR-2 cells | Colon Cancer Liver Metastasis | 1 | 2018-01-15actual | 2024-02-28 |
| Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.NCT01768702Efficacy between groups post-index procedureRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Injection of C3BS-CQR-1, Sham, no injection | Heart Failure | 315 | Aug 2017actual | 2018-06-01 |
| C-Cure Clinical TrialNCT00810238Change in left ventricular ejection fractionRandomized · Single-masked · Treatment | Phase 2/3 | Completed | Biological: C-Cure | Heart Failure Class II or III | 240 | Jul 2010actual | 2012-09-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19